Abstract Number: 2835 • 2013 ACR/ARHP Annual Meeting
Safety Of Gardasil® Vaccine In Systemic Lupus Erythematosus
Background/Purpose: Cervical neoplasia is increased in women with SLE presumably due to cervical infection with oncogenic Human Papillomavirus (HPV) types which persist in an immunosuppressed…Abstract Number: 2836 • 2013 ACR/ARHP Annual Meeting
Development of a Health Index in Patients With Ankylosing Spondylitis (ASAS HI) – Final Result of a Global Initiative Based On the International Classification of Functioning, Disability and Health (ICF) Guided By Assesment of Spondyloarthritis International Society (ASAS)
Background/Purpose: The impact of ankylosing spondylitis (AS) on a patient’s life can be considerable. Patients suffer from pain, stiffness and fatigue, are limited in their…Abstract Number: 2796 • 2013 ACR/ARHP Annual Meeting
Effects Of BAFF Inhibition On B Cell Selection In Murine SLE
Background/Purpose: BAFF inhibition is a new B cell targeted therapy approved for the treatment of moderately active SLE. Although BAFF regulates selection of naïve autoreactive…Abstract Number: 2797 • 2013 ACR/ARHP Annual Meeting
B-Lymphocyte Stimulator and A Proliferation Inducing Ligand In Lupus Nephritis: Low Serum Levels Of BLyS Predict Treatment Response
Background/Purpose: B-lymphocytes have a pivotal role in the pathogenesis of Systemic Lupus Erythematosus (SLE). B-Lymphocyte Stimulator (BLyS) has an important role in the activation, differentiation…Abstract Number: 2798 • 2013 ACR/ARHP Annual Meeting
Bone Marrow In Systemic Lupus Erythematosus Patients Contain a Highly Elevated Proportion Of Somatically Mutated, Activated Naive Cells Comprised Of Substantial Clonal Expansions
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease where autoreactive antibodies are produced as a result of abnormal B cell activation and broken self-tolerance. This…Abstract Number: 2799 • 2013 ACR/ARHP Annual Meeting
Identification Of IL-10 Producing Plasma Cells In Human and Its Deficiency In Systemic Lupus Erythematosus Patients
Background/Purpose: Regulatory B cells are active participants in down-regulating inflammation and autoimmunity, through the production of IL-10. Despite intensive studies in mice, there is only…Abstract Number: 2800 • 2013 ACR/ARHP Annual Meeting
Dose-Response Effects Of Denosumab, a Novel Subcutaneous RANKL Inhibitor, On The Progression Of Bone Erosion In Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate: Results Of Phase II DRIVE Study – A Twelve Month Placebo Controlled, Randomized, Double Blind Study
Background/Purpose: Denosumab is a fully human monoclonal antibody (IgG2 subclass) that binds specifically to RANKL. It inhibits osteoclast-induced bone resorption by preventing the binding of…Abstract Number: 2801 • 2013 ACR/ARHP Annual Meeting
Comparative Longitudinal Analysis Of Periarticular Bone Structure In Patients Treated With Methotrexate In Combination Of Either TNF Blockers Or Tocilizumab
Background/Purpose: Inhibition of tumor necrosis factor alpha (TNFi) and interleukin-6 receptor (IL6Ri, tocilzumab) are among the most potent therapeutic strategies in patients with rheumatoid arthritis…Abstract Number: 2802 • 2013 ACR/ARHP Annual Meeting
A Treat-To-Target Strategy With Methotrexate and Intra-Articular Triamcinolone With Or Without Added Adalimumab Reduces Synovitis, Osteitis and Tenosynovitis and Halts Structural Damage Progression In Early Rheumatoid Arthritis: The Opera Magnetic Resonance Imaging Sub-Study
Background/Purpose: The aim was to investigate if a treat-to-target strategy with methotrexate and intra-articular glucocorticoid suppressed synovitis and osteitis, and halted structural damage progression in…Abstract Number: 2803 • 2013 ACR/ARHP Annual Meeting
Can Ultrasonographic Findings Predict Response To Tumor Necrosis Factor-α Inhibitor Treatment In Rheumatoid Arthritis?
Background/Purpose: Tumor necrosis factor-α inhibitors (TNFi) are highly effective in patients with rheumatoid arthritis (RA), while not effective in all, with predictors of response being…Abstract Number: 2804 • 2013 ACR/ARHP Annual Meeting
Radiological Outcome Of Joints With MRI Detected Subclinical Inflammation In Early Arthritis Patients
Background/Purpose: Extremity-MRI is becoming important in Rheumatoid Arthritis (RA) research as it is a sensitive tool to assess inflammation. Inflammation is measured by three features:…Abstract Number: 2805 • 2013 ACR/ARHP Annual Meeting
Synovial Explant Inflammatory Mediator Production Is Associated With Synovitis While Not With Bone Marrow Edema In Rheumatoid Arthritis: A Cross Sectional Study
Background/Purpose: Synovitis and bone damage may represent two distinct but overlapping pathological processes in rheumatoid arthritis (RA). Whereas the bulk of synovial cells contribute to…Abstract Number: 2806 • 2013 ACR/ARHP Annual Meeting
Low Risk Of Hepatitis B Virus Surface Antigen Seroreversion In HBsAg Negative/Anti-Hbc Positive Carriers Undergoing Rituximab For Rheumatoid Arthritis
Background/Purpose: B cell-targeted therapy using rituximab (RTX), anti-CD20 monoclonal antibody, is an effective treatment for Rheumatoid arthritis (RA). However, the safety of such therapy in…Abstract Number: 2807 • 2013 ACR/ARHP Annual Meeting
Management Of Vertebral Osteomyelitis: A Randomized Clinical Trial Comparing 6 Versus 12 Weeks Of Antibiotic Treatment
Background/Purpose: As for most of bone and joint infection, optimal treatment duration for vertebral osteomyelitis (VO) is unknown. In an era of increasing bacterial resistance,…Abstract Number: 2808 • 2013 ACR/ARHP Annual Meeting
Favorable Outcome Of Hepatitis E Virus Infection In Patients With Inflammatory Arthritides Treated With Immunosupressants
Background/Purpose: In inflammatory rheumatic diseases, the prevalence, clinical presentation and outcome of hepatitis E, an ubiquitous viral infection, remain unknown. We therefore addressed these issues…
ACR Meeting Abstracts